Evidence map›Paper›PMID 19850873›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease.

Bingning Dong, Pradip K Saha, Wendong Huang, Wenling Chen, Lutfi A Abu-Elheiga, Salih J Wakil, Robert D Stevens, Olga Ilkayeva, Christopher B Newgard, Lawrence Chan and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 259 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Bile acid regulation of xenobiotic nuclear receptors on the expressions of orosomucoids in the liver.American journal of physiology. Endocrinology and metabolism · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Bilirubin metabolism in relation to cancer.Frontiers in oncology · 2025
    Review
  15. Article
  16. Article
  17. Regulation of hepatic xenosensor function by HNF4alpha.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Article
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Bingning DongDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Pradip K Saha
Wendong Huang
Wenling Chen
Lutfi A Abu-Elheiga
Salih J Wakil
Robert D Stevens
Olga Ilkayeva
Christopher B Newgard
Lawrence Chan
David D Moore
Baylor College of Medicine · USDiabetes Australia · AUDuke University Hospital · USCity Of Hope National Medical Center · USDuke University · USThe University of Texas Southwestern Medical Center · US

Funding

Diabetes Endocrinology Research CenterP30DK079638 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHAN, LAWRENCE · 2008 to 2012
$6.4M
Metabolic Regulation by the Nuclear Receptor CARR01DK046546 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MOORE, DAVID D · 1995 to 2014
$4.9M
NOVEL THERAPY FOR DIABETESR01DK068037 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHAN, LAWRENCE · 2004 to 2008
$2.1M
NIDDK NIH HHS P30 DK079638NIDDK NIH HHS P30-DK079638NIDDK NIH HHS R01 DK046546NIDDK NIH HHS R01 DK068037NIDDK NIH HHS R01-DK068037NIDDK NIH HHS R01 DK46546
6 · The paper itself

Abstract

Constitutive androstane receptor CAR (NR1I3) has been identified as a central mediator of coordinate responses to xenobiotic and endobiotic stress. Here we use leptin-deficient mice (ob/ob) and ob/ob, CAR(-/-) double mutant mice to identify a metabolic role of CAR in type 2 diabetes. Activation of CAR significantly reduces serum glucose levels and improves glucose tolerance and insulin sensitivity. Gene expression analyses and hyperinsulinemic euglycemic clamp results suggest that CAR activation ameliorates hyperglycemia by suppressing glucose production and stimulating glucose uptake and usage in the liver. In addition, CAR activation dramatically improves fatty liver by both inhibition of hepatic lipogenesis and induction of beta-oxidation. We conclude that CAR activation improves type 2 diabetes, and that these actions of CAR suggest therapeutic approaches to the disease.

Indexed as

AnimalsBlood GlucoseConstitutive Androstane ReceptorDiabetes Mellitus, ExperimentalFatty LiverGene Expression RegulationGlucose Tolerance TestInsulinLipogenesisLiverMiceMice, ObeseOxidation-ReductionReceptors, Cytoplasmic and NuclearSulfotransferasesBlood GlucoseConstitutive Androstane ReceptorInsulinNr1i3 protein, mouseReceptors, Cytoplasmic and NuclearSulfotransferases

Identifiers

PMID19850873
PMCPMC2773998
OpenAlexW2060802146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.